Roquinimex

Jump to: navigation, search
Roquinimex
Roquinimexpng.png
Clinical data
ATC code
Pharmacokinetic data
Elimination half-life26-42 hours
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC18H16N2O3
Molar mass308.331 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Roquinimex

Articles

Most recent articles on Roquinimex

Most cited articles on Roquinimex

Review articles on Roquinimex

Articles on Roquinimex in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Roquinimex

Images of Roquinimex

Photos of Roquinimex

Podcasts & MP3s on Roquinimex

Videos on Roquinimex

Evidence Based Medicine

Cochrane Collaboration on Roquinimex

Bandolier on Roquinimex

TRIP on Roquinimex

Clinical Trials

Ongoing Trials on Roquinimex at Clinical Trials.gov

Trial results on Roquinimex

Clinical Trials on Roquinimex at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Roquinimex

NICE Guidance on Roquinimex

NHS PRODIGY Guidance

FDA on Roquinimex

CDC on Roquinimex

Books

Books on Roquinimex

News

Roquinimex in the news

Be alerted to news on Roquinimex

News trends on Roquinimex

Commentary

Blogs on Roquinimex

Definitions

Definitions of Roquinimex

Patient Resources / Community

Patient resources on Roquinimex

Discussion groups on Roquinimex

Patient Handouts on Roquinimex

Directions to Hospitals Treating Roquinimex

Risk calculators and risk factors for Roquinimex

Healthcare Provider Resources

Symptoms of Roquinimex

Causes & Risk Factors for Roquinimex

Diagnostic studies for Roquinimex

Treatment of Roquinimex

Continuing Medical Education (CME)

CME Programs on Roquinimex

International

Roquinimex en Espanol

Roquinimex en Francais

Business

Roquinimex in the Marketplace

Patents on Roquinimex

Experimental / Informatics

List of terms related to Roquinimex

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Roquinimex (Linomide) is a quinoline derivative immunostimulant which increases NK cell activity and macrophage cytotoxicity. It also inhibits angiogenesis and reduces the secretion of TNF alpha.

Roquinimex has been investigated as a treatment for some cancers (including as adjuvant therapy after bone marrow transplantation in acute leukemia) and autoimmune diseases, such as multiple sclerosis and recent-onset type I diabetes. Several trials have been terminated due to serious cardiovascular toxicity.